English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

SummaryBackgroundTrimodality therapy with surgery and neoadjuvant chemoradiotherapy (nCRT) has been developed to improve survival outcomes in advanced esophageal cancer. We hypothesized that the effect of surgery plus nCRT with oral fluoropyrimidine (S-1) and low-dose cisplatin will be effective with low toxic effects in patients with esophageal cancer as well as gastric cancer.MethodsThis cohort study included 28 Japanese patients who underwent nCRT plus esophagectomy for esophageal cancer in preoperative clinical Stage II/III. They received only one cycle of S-1 and low-dose cisplatin concurrently, followed by surgery 3–4 weeks after completion of nCRT (the doses of radiotherapy were 20 or 30 Gy). We examined the clinical efficacy and safety of nCRT plus esophagectomy.ResultsAll patients had squamous cell carcinoma and they all completed nCRT and underwent esophagectomy. No treatment-related deaths were observed. The response rate to nCRT was 92.9%. The 1-year, 3-year, and 5-year overall survival rates were 84.4%, 67.0%, and 67.0%, respectively for Stage II/III.ConclusionToxicity of nCRT was acceptable, and the efficacy and prognosis were favorable, particularly as we performed only one cycle of neoadjuvant chemotherapy with low doses of radiotherapy

Study of neoadjuvant chemoradiotherapy with combined S-1 and low-dose cisplatin for patients with clinical stage II/III esophageal cancer